Other indicators for screening PC in patients with T2DM include BMI; age of T2DM onset; hepatitis B virus infection; and total bilirubin, alanine aminotransferase, creatinine, apolipoprotein A1, and leukocyte (WBC) levels (78). This evidence concerns the gene APOA1 and type 2 diabetes mellitus.